MedTrace Logo

Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine

NCT07758972 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2026-08-11

No results posted yet for this study

Summary

The main goal of this trial is to evaluate the safety and immunogenicity of the candidate N. gonorrhoeae vaccine, LTB-NG6.

Conditions

  • Neisseria Gonorrhea

Interventions

BIOLOGICAL

LTB-NG6

LTB-NG6 administrated at 5 different doses

OTHER

Sodium Chloride 0.9%

sodium chloride 0.9% used as a diluent in LTB-NG6 and as a placebo

Sponsors & Collaborators

  • Nuvisan, Germany

    collaborator UNKNOWN

  • Wellcome Trust

    collaborator OTHER

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • Novo Nordisk Foundation

    collaborator OTHER

  • LimmaTech Biologics AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-19
Primary Completion
2027-04-26
Completion
2027-09-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07758972 on ClinicalTrials.gov